Balanced Anesthesia Using Intravenous Clonidine in Breast Conservation Surgery with Minimal Blood Loss : A Randomized Control trial.

HCG Manavata Cancer Centre0 个研究点目标入组 80 人开始时间: 待定最近更新: 2023年5月1日

试验速览

暂无简介。

•1.Operable Breast Cancer Patients undergoing Breast Conservation Surgery in Adjuvant and Neoadjuvant setting.
•2.Age 18 yrs â?? 80 yrs
•3.Patientâ??s ASA between I â?? III
•4.ECOG Performance Status < 0 â?? 2
•5.Estimated Life Expectancy > 6 months based on clinical evaluation by the Investigator.
•6.No persistent toxicities from prior medications at screening.
•7.Able to comply to study requirement in opinion of Investigator.
•8.Hematology, Sr. Creatinine and R BSL within Normal Limits
•9.Negative Pregnancy tests in sexually active women
•10.Patient able to understand and provide written informed consent prior to participation in the study.

•1.Uncontrolled DM with Autonomic Dysfunction
•2.Uncontrolled HTN
•4.Heart Block
•5.Patients on Beta Blockers
•6.History of CVA or DVT within last 3 months.
•7.Pregnant or Breast Feeding Women
•8.Hypersensitivity to Inj. Clonidine, Inj. Labetelol, Inj. Fentanyl.
•9.Active Opprtunistic Infections.
•10.Impaired Cardiac Function within last 6 months.
•11.Drug Abuse â?? Tobacco, Alcohol or any other recreational drugs
•12.Positive or reactive test for HIV, HAV, HCV or HBsAg
•13.Receipt of any other IP or participation in other drug trial within 30 days or 5 half lives , whichever is greater, prior to receiving drug in this study.
•14.Any other primary tumours.
•15.Other serious illness that would prohibit understanding and giving informed consent.

发起方

HCG Manavata Cancer Centre